Printer Friendly

BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES AWARD TO CANCER RESEARCHER

 PRINCETON, N.J., April 19 /PRNewswire/ -- The Bristol-Myers Squibb Company (NYSE: BMY) has announced that Arnold J. Levine, Ph.D., of Princeton University is the recipient of the 1994 Award for Distinguished Achievement in Cancer Research for his work with the cancer gene p53, believed to be one of the most important genes in the development of human cancers.
 Dr. Levine is one of two researchers whose laboratories discovered p53 in 1979. He later cloned the gene, making future experiments with it possible, and discovered that it is actually a tumor suppressor rather than an oncogene, which promotes cell growth, as researchers had thought.
 In their normal state, tumor suppressors, such as p53, and the recently discovered p16, prevent cancer from developing by controlling cell growth. Cancer researchers are increasingly looking to tumor suppressors as the key to understanding how cancer develops.
 Dr. Levine will receive the Bristol-Myers Squibb award Wednesday. The award is part of a no-strings-attached biomedical research grants program that since 1977 has committed more than $53 million in funds.
 -0- 4/19/94
 /CONTACT: Leigh Ann Flora of PCI, 312-558-1770, for Bristol-Myers Squibb Company/
 (BMY)


CO: Bristol-Myers Squibb Company ST: New Jersey IN: MTC SU:

CB -- NY121 -- 7150 04/19/94 16:40 EDT
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 19, 1994
Words:208
Previous Article:HARRIS RAISES PRIME TO 6.75 PERCENT; HARRIS SMALL BUSINESS LENDING RATE REMAINS HALF PERCENT BELOW WALL STREET JOURNAL PRIME
Next Article:FEW EMPLOYERS SAY THEY ARE VERY FAMILIAR WITH HEALTH CARE REFORM
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters